Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Kalvista Pharmaceuticals Inc (NQ: KALV ) 11.78 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Kalvista Pharmaceuticals Inc < Previous 1 2 3 4 5 Next > KalVista Pharmaceuticals to Present at 13th Annual Jefferies Healthcare Conference June 01, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Announces Changes to Board of Directors May 27, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Announces Non-Proprietary Name Selection for KVD900 May 17, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals to Present at 21st Annual Needham Virtual Healthcare Conference April 11, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 04, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Announces Publication of Additional KVD900 Data in Clinical & Experimental Allergy March 22, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference February 03, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022 February 02, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 02, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Announces Publication of Oral HAE Therapy KVD900 Phase 1 Data in Journal of Allergy and Clinical Immunology January 24, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 04, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Second Fiscal Quarter Results December 09, 2021 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 03, 2021 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Provides Progress Update on KVD900 for Oral On-Demand Treatment of Hereditary Angioedema November 10, 2021 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals to Present at Upcoming Investor Conferences November 09, 2021 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Presents Data Demonstrating KVD900 Achieves Rapid Exposure and Improves Outcomes as Oral On-Demand Treatment of HAE November 08, 2021 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 04, 2021 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 04, 2021 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference September 21, 2021 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Announces the Lifting of FDA Clinical Hold for Phase 2 Trial of KVD824 September 14, 2021 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports First Fiscal Quarter Results September 09, 2021 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 02, 2021 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema August 23, 2021 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 09, 2021 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results July 13, 2021 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE July 12, 2021 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals to Present Data at the European Academy of Allergy and Clinical Immunology (EAACI) June 28, 2021 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop June 05, 2021 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference May 27, 2021 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals to Present Clinical Data of KVD900 for the Oral Treatment of Hereditary Angioedema at the 12th C1-Inhibitor Deficiency & Angioedema Workshop May 10, 2021 From KalVista Pharmaceuticals, Inc. Via Business Wire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.